Identification of potential synthetic lethal genes to p53 using a computational biology approach

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Wang, Xiaosheng ^a   Simon, Richard ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Computational biology; Gene expression profiles; p53 mutations; Synthetic lethal genes

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; APRINOCARSEN; AXITINIB; BRYOSTATIN; CISPLATIN; ENZASTAURIN; EVEROLIMUS; FLAVOPIRIDOL; GEMCITABINE; HYMENIALDISINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MERCAPTOPURINE; MIDOSTAURIN; NOCODAZOLE; OLOMOUCINE; PACLITAXEL; PAZOPANIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; QUERCETIN; RAPAMYCIN; RIDAFOROLIMUS; RNA; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DRUG SENSITIVITY; DRUG TARGETING; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC SELECTION; HUMAN; HUMAN CELL; LETHAL GENE; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; P53 GENE; PRIORITY JOURNAL; RNA SEQUENCE; SOMATIC MUTATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE SILENCING; GENES, LETHAL; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883631172     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-30     Document Type: Article

References (83)

1. p53 mutations in human cancers. Hollstein M, et al. Science (New York, N Y) 1991 253 5015 49 53
2. The concept of synthetic lethality in the context of anticancer therapy. Kaelin WG Jr, Nat Rev Cancer 2005 5 9 689 698
3. Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Canaani D, Br J Cancer 2009 100 8 1213 1218
4. Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Mizuarai S, et al. Curr Mol Med 2008 8 8 774 783
5. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Mizuarai S, Yamanaka K, Kotani H, Cancer Res 2006 66 12 6319 6326
6. RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Eguchi T, et al. Oncogene 2007 26 4 509 520
7. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Benjami Y, Hochberg Y, J R Stat Soc B 1995 57 289 300
8. Analysis of gene expression data using BRB-array tools. Simon R, et al. Cancer Informatics 2007 3 11 17
9. Cell miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Reinhold WC, et al. Cancer Res 2012 72 14 3499 3511
10. Cell miner: a relational database and query tool for the NCI-60 cancer cell lines. Shankavaram UT, et al. BMC Genomics 2009 10 277
11. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Liu X, Erikson RL, Proc Natl Acad Sci USA 2003 100 10 5789 5794
12. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Luo J, et al. Cell 2009 137 5 835 848
13. Gene expression patterns associated with p53 status in breast cancer. Troester MA, et al. BMC cancer 2006 6 276
14. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Langerod A, et al. Breast Cancer Res 2007 9 3 30
15. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Sur S, et al. Proc Natl Acad Sci USA 2009 106 10 3964 3969
16. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Brosh R, Rotter V, Mol Biosyst 2010 6 1 17 29
17. The p53 response element and transcriptional repression. Wang B, et al. Cell cycle (Georgetown, Tex) 2010 9 5 870 879
18. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Peter B, et al. Haematologica 2011 96 5 672 680
19. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Lenart P, et al. Curr Biol 2007 17 4 304 315
20. Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Mikolcevic P, et al. Mol Cell Biol 2012 32 4 868 879
21. Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/beta-catenin signaling. Berndt JD, et al. J Cell Biol 2011 194 5 737 750
22. The coordinate regulation of the p53 and mTOR pathways in cells. Feng Z, et al. Proc Natl Acad Sci USA 2005 102 23 8204 8209
23. Upstream and downstream of mTOR. Hay N, Sonenberg N, Genes Dev 2004 18 16 1926 1945
24. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Feng Z, Cold Spring Harb Perspect Biol 2010 2 2 001057
25. DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. Sanjo H, Kawai T, Akira S, J Biol Chem 1998 273 44 29066 29071
26. SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. Nakamura T, Saito H, Takekawa M, Nat Commun 2013 4 1775
27. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Robinson DR, et al. Nat Med 2011 17 12 1646 1651
28. A human homolog of the yeast Ssk2/Ssk22 MAP kinase kinase kinases, MTK1, mediates stress-induced activation of the p38 and JNK pathways. Takekawa M, Posas F, Saito H, EMBO J 1997 16 16 4973 4982
29. Automated screening of microtubule growth dynamics identifies MARK2 as a regulator of leading edge microtubules downstream of Rac1 in migrating cells. Nishimura Y, et al. PLoS One 2012 7 7 41413
30. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. Spurgers KB, et al. J Biol Chem 2006 281 35 25134 25142
31. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Di Agostino S, et al. Cancer cell 2006 10 3 191 202
32. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Li A, et al. Am J Hum Genet 2003 72 3 691 703
33. A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Hsueh KW, et al. Biochim Biophys Acta 2013 1834 2 508 515
34. Aurora A, meiosis and mitosis. Crane R, et al. Biol Cell 2004 96 3 215 229
35. p53-dependent apoptosis in response to spindle damage is linked to loss of Bub1. Beeharry N, Yen TJ, Cancer Biol Ther 2009 8 7 645 647
36. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Gui JF, Lane WS, Fu XD, Nature 1994 369 6482 678 682
37. Targeting the mitotic checkpoint to kill tumor cells. Janssen A, Kops GJ, Medema RH, Hormones & cancer 2011 2 2 113 116
38. TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Huang YF, Chang MD, Shieh SY, Mol Cell Biol 2009 29 11 2935 2944
39. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Lopez-Borges S, Lazo PA, Oncogene 2000 19 32 3656 3664
40. Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. Barcia R, et al. Arch Biochem Biophys 2002 399 1 1 5
41. Plk4-induced centriole biogenesis in human cells. Kleylein-Sohn J, et al. Dev Cell 2007 13 2 190 202
42. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Tabach Y, et al. Mol Syst Biol 2005 1 2005 0022
43. Surveillance mechanism linking Bub1 loss to the p53 pathway. Gjoerup OV, et al. Proc Natl Acad Sci USA 2007 104 20 8334 8339
44. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Bonte D, et al. Neoplasia 2008 10 9 920 931
45. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Montagnoli A, et al. Cancer Res 2004 64 19 7110 7116
46. A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. Krastev DB, et al. Nat Cell Biol 2011 13 7 809 818
47. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Wang Y, Decker SJ, Sebolt-Leopold J, Cancer Biol Ther 2004 3 3 305 313
48. Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. Kim JM, Yamada M, Masai H, Mutat Res 2003 532 1-2 29 40
49. Polo-like kinases and the orchestration of cell division. Barr FA, Sillje HH, Nigg EA, Nat Rev Mol Cell Biol 2004 5 6 429 440
50. Mitotic Kinases and p53 Signaling. Ha GH, Breuer EK, Biochem Res Int 2012 2012 195903
51. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. Wilkinson MG, Millar JB, FASEB J 2000 14 14 2147 2157
52. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1. Gulati AP, et al. Mol Carcinog 2006 45 1 26 37
53. Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Lee SW, et al. Proc Natl Acad Sci USA 2000 97 15 8302 8305
54. The functional interactions between the p53 and MAPK signaling pathways. Wu GS, Cancer Biol Ther 2004 3 2 156 161
55. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Degenhardt Y, et al. Mol Cancer Ther 2010 9 7 2079 2089
56. Sheelagh F, et al. Potent and selective small molecule inhibitors of polo-like kinase 1: biological characterization. in AACR 103rd annual meeting Chicago: IL: American Association for Cancer Research 2012
57. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Burmer GC, Loeb LA, Proc Natl Acad Sci USA 1989 86 7 2403 2407
58. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Almoguera C, et al. Cell 1988 53 4 549 554
59. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Tam IY, et al. Clin Cancer Res 2006 12 5 1647 1653
60. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Rodriguez-Acebes S, et al. Am J Pathol 2010 177 4 2034 2045
61. Targeting mTOR signaling for cancer therapy. Huang S, Houghton PJ, Curr Opin Pharmacol 2003 3 4 371 377
62. Targeting the mTOR signaling network for cancer therapy. Meric-Bernstam F, Gonzalez-Angulo AM, J Clin Oncol 2009 27 13 2278 2287
63. Aurora kinase inhibitors-rising stars in cancer therapeutics? Dar AA, et al. Mol Cancer Ther 2010 9 2 268 278
64. Targeting the protein kinase C family: are we there yet? Mackay HJ, Twelves CJ, Nat Rev Cancer 2007 7 7 554 562
65. Protein kinase C (PKC) family in cancer progression. Koivunen J, Aaltonen V, Peltonen J, Cancer Lett 2006 235 1 1 10
66. Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. Chua BT, et al. Mol Cancer 2009 8 131
67. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. Gallego-Ortega D, et al. PloS one 2009 4 11 7819
68. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Glunde K, et al. Cancer Res 2005 65 23 11034 11043
69. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Ramirez de Molina A, et al. Int J Biochem Cell Biol 2008 40 9 1753 1763
70. Raf kinases in cancer-roles and therapeutic opportunities. Maurer G, Tarkowski B, Baccarini M, Oncogene 2011 30 32 3477 3488
71. Transcription regulation by mutant p53. Weisz L, Oren M, Rotter V, Oncogene 2007 26 15 2202 2211
72. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Sullivan KD, et al. Nat Chem Biol 2012 8 7 646 654
73. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Toledo LI, et al. Nat Struct Mol Biol 2011 18 6 721 727
74. Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Mizuarai S, Kotani H, Hum Genet 2010 128 6 567 575
75. Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Wang Y, et al. Mol Cancer 2009 8 8
76. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Scian MJ, et al. Oncogene 2004 23 25 4430 4443
77. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Roh JL, et al. Oral Oncol 2011 47 1 8 15
78. Restoration of the transcription activation function to mutant p53 in human cancer cells. Abarzua P, et al. Oncogene 1996 13 11 2477 2482
79. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Bossi G, Sacchi A, Head Neck 2007 29 3 272 284
80. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Bykov VJ, et al. Nat Med 2002 8 3 282 288
81. Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Rosenfeld MR, et al. Neurology 1995 45 8 1533 1539
82. Restoration of p53 function leads to tumour regression in vivo. Ventura A, et al. Nature 2007 445 7128 661 665
83. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Wiman KG, Adv Cancer Res 2007 97 321 338